Incidence and pattern of "de novo"hepatocellular carcinoma in HCV patients treated with oral DAAs,

This study evaluates the possibility of increased risk of HCC during and after DAAs treatment in HCV patients with advanced liver disease

Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study

Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of Hepatocellular carcinoma (HCC) during/after therapy with DAAs. Aim of this study was to evaluate incidence of newly diagnosed hepatocellular carcinoma and associated risk factors in patients with advanced hepatitis C treated with DAAs

Efficacy and safety of DAA-based oral therapy i9n a large cohort of HCV patients treated in clinical practice in Italy and monitored by the NAVIGATORE web-platform.

The efficacy and safety of DAAs oral therapy is monitored by a web-platform named NAVIGATOR